An announcement from ImmunoPrecise Antibodies ( (IPA) ) is now available.
ImmunoPrecise Antibodies Ltd. has announced a strategic partnership with RIBOPRO to advance mRNA-driven antibody discovery, aiming to revolutionize the development of therapeutic antibodies. This collaboration combines RIBOPRO’s mRNA and lipid nanoparticle technologies with IPA’s AI-driven and wet-lab capabilities to improve antigen presentation and immune responses, potentially accelerating the discovery of novel therapeutics and strengthening their position in the field of precision therapeutics.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a global leader in AI-powered antibody discovery and development, focusing on integrating advanced technologies to enhance therapeutic antibody discovery.
YTD Price Performance: -9.78%
Average Trading Volume: 6,419,709
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.59M
Learn more about IPA stock on TipRanks’ Stock Analysis page.